| abstract |
The present invention relates to spiro-oxazolones which act as V1a receptor modulators, in particular as V1a receptor antagonists, to their preparation, to pharmaceutical compositions containing them and to their use as medicaments. The present compounds are useful as therapeutic agents that act primarily and pivotally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorder, obsessive compulsive disorder, autism spectrum disorders, schizophrenia, aggressive behavior and phase change sleep disorders, especially mental illnesses. |